Vol 5, No 4 (2020)
Invited editorial
Published online: 2020-10-15

open access

Page views 602
Article views/downloads 630
Get Citation

Connect on Social Media

Connect on Social Media

Levosimendan comes of age: twenty years in clinical use

F. Guarracino1, J. Alvarez2, D. Bettex3, S. Bouchez4, S. Fruhwald5, M. Girardis6, M. Heringlake7, A. Herpain8, S. E. Ricksten9, W. Toller5
Medical Research Journal 2020;5(4):219-221.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Tritapepe L, Pollesello P, Grossini E. The inodilator levosimendan: 20 years of experience in various settings of cardiac care. Med Res J. 2020; 5(3): 1–2.
  2. Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012; 159(2): 82–87.
  3. Li H, Duan Y, Chen B, et al. New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis. Medicine (Baltimore). 2020; 99(5): e18341.
  4. Sanfilippo F, Knight JB, Scolletta S, et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Crit Care. 2017; 21(1): 252.
  5. Herpain A, Bouchez S, Girardis M, et al. Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper. J Cardiovasc Pharmacol. 2019; 73(1): 3–14.
  6. Lim JuY, Deo SV, Rababa'h A, et al. Levosimendan Reduces Mortality in Adults with Left Ventricular Dysfunction Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis. J Card Surg. 2015; 30(7): 547–554.
  7. Guarracino F, Heringlake M, Cholley B, et al. Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice. J Cardiovasc Pharmacol. 2018; 71(1): 1–9.
  8. van Diepen S, Mehta RH, Leimberger JD, et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. J Thorac Cardiovasc Surg. 2020; 159(6): 2302–2309.e6.
  9. Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013; 27(6): 581–590.
  10. Gordon A, Santhakumaran S, Al-Beidh F, et al. Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT. Efficacy and Mechanism Evaluation. 2018; 5(6): 1–94.
  11. Sangalli F, Bellani G, Affronti A, et al. Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: current evidence and future directions. Minerva Anestesiol. 2020; 86(6): 645–651.
  12. Roesthuis L, van der Hoeven H, Sinderby C, et al. Effects of levosimendan on respiratory muscle function in patients weaning from mechanical ventilation. Intensive Care Med. 2019; 45(10): 1372–1381.
  13. Distelmaier K, Roth C, Schrutka L, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth. 2016; 117(1): 52–58.
  14. Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013; 41(10): 2328–2335.
  15. Lannemyr L, Ricksten SE, Rundqvist B, et al. Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial. J Am Heart Assoc. 2018; 7(16): e008455.
  16. Lannemyr L, Bragadottir G, Redfors B, et al. Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery. J Crit Care. 2020; 57: 225–230.